The portable X-ray and CT scan device market is steadily growing in importance. According to the companies, it should be heading up by 7.6 percent CAGR to 2020, reaching $8.41 billion.

MedyMatch was also in the news this month when it and IBM Watson Health announced a collaboration in which Watson Health will distribute the MedyMatch clinical support bleed application globally through its vendor-neutral sales channels for integration into its other offerings.


"MedyMatch is focused on those clinical areas where time is of the essence, when access to expert physicians may not be feasible, and when decision in treatment can cause more harm to the patient than doing nothing at all," Gene Saragnese, chairman & CEO, MedyMatch Technology told HCB News.

The goal is to provide an all-important "second set of artificial eyes" when time is critical.

"For the physician, it is the confidence of knowing that they are not alone. In that moment of decision to treat, or not treat the patient, knowing that there is a high probability of either the presence of a bleed or no indication of brain bleed, may be the factor that saves the patient’s life," he said.

When MedyMatch unveiled its software in November, 2016, Dr. Jacob Cohen, chief technical officer of MedyMatch, noted that, "consideration of the whole patient differentiates MedyMatch from traditional computer assisted detection (CAD) applications." "While traditional CADs strictly focus on pixel data, MedyMatch's technology applies deep learning and computer vision, also known as 'Deep Vision,' to interpret the full richness of the 3-D imaging data, together with the patient's Electronic Medical Record, allowing the system to consider the 'whole' patient."

Back to HCB News

Business Affairs Homepage